Research Topics
Species | JASON R GOTLIBSummaryAffiliation: Stanford University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and managementJason Gotlib
Division of Hematology, Stanford University Medical Center, Palo Alto, CA, USA
Am J Hematol 87:903-14. 2012..Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic role in primary eosinophilic diseases and HES has yet to be established...
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementJason Gotlib
Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
Blood 103:2879-91. 2004..This review examines the current state of knowledge of HES and CEL and the implications of the FIP1L1-PDGFRA discovery on their diagnosis, classification, and management...- World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and managementJason Gotlib
Division of Hematology, Department of Medicine, Stanford University School of Medicine Stanford Cancer Center, Stanford, California 94305 5821, USA
Am J Hematol 86:677-88. 2011..Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established... - Eosinophilic myeloid disorders: new classification and novel therapeutic strategiesJason Gotlib
Stanford University School of Medicine, Stanford Cancer Center, Stanford, California, USA
Curr Opin Hematol 17:117-24. 2010..The aim of this brief review is to evaluate recent developments in the classification and treatment of eosinophilic myeloid disorders in the context of reactive, lymphocyte-variant, and idiopathic eosinophilias... - A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromesJason Gotlib
Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
Am J Hematol 84:15-20. 2009..Our data indicate that weekly weight-based dosing of DA, with the addition of G-CSF in selected individuals, can be an effective erythropoietic option in a high proportion of lower-risk MDS patients... - Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophiliasJ Gotlib
Department of Medicine, Division of Hematology, Stanford Cancer Center, Stanford, CA 94305 5821, USA
Leukemia 22:1999-2010. 2008.... - KIT mutations in mastocytosis and their potential as therapeutic targetsJason Gotlib
Stanford Cancer Center, Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2327B, Stanford, CA 94305 5821, USA
Immunol Allergy Clin North Am 26:575-92. 2006..In addition, the generation of murine models that recapitulate human mastocytosis should accelerate preclinical testing of novel agents... - Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapyJason Gotlib
Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2327B, Stanford, CA 94305 5821, USA
Best Pract Res Clin Haematol 19:535-69. 2006.... - Molecular classification and pathogenesis of eosinophilic disorders: 2005 updateJason Gotlib
Stanford Cancer Center, 875 Blake Wilbur Drive, Rm 2327B, Stanford, CA 94305 5821, USA
Acta Haematol 114:7-25. 2005..Success in establishing the molecular basis of a group of once seemingly heterogeneous diseases has now the laid the foundation for establishing a semi-molecular classification scheme of eosinophilic disorders... - Farnesyltransferase inhibitor therapy in acute myelogenous leukemiaJason Gotlib
Division of Hematology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Curr Hematol Rep 4:77-84. 2005..Preclinical concepts related to the development of FTIs, the rationale for their use in AML, and efficacy and safety results from recent clinical trials are evaluated in this paper... 
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutationJason Gotlib
Department of Medicine, Division of Hematology, Stanford University, Stanford Cancer Center, 875 Blake Wilbur Dr, Rm 2327B, Stanford, CA 94305 5821, USA
Blood 106:2865-70. 2005..This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by clonal evolution in the advanced leukemic phase of this disease...- Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemiaMICHAELA LIEDTKE
Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Haematologica 97:30-7. 2012.... - Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaDaniel A Pollyea
Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
Haematologica 98:591-6. 2013..In conclusion, a sequential combination of azacitidine plus lenalidomide has clinical activity in older patients with acute myeloid leukemia, and further studies of this combination are underway... - DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groupsRobert S Ohgami
Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Br J Haematol 159:182-90. 2012.... - Treatment advances have not improved the early death rate in acute promyelocytic leukemiaJames Scott McClellan
Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
Haematologica 97:133-6. 2012..Our findings show that early death is now the greatest contributor to treatment failure in this otherwise highly curable form of leukemia... - Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosisAnimesh Pardanani
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 29:789-96. 2011..Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor...
Research Grants
- FTI Biology & Treatment of Myeloproliferative DisordersJason Gotlib; Fiscal Year: 2005..If clinically efficacious, further studies of R115777 in MPDs will be warranted...